1887
Volume 2013, Issue 2
  • ISSN: 2305-7823
  • E-ISSN:

Abstract

Atrial fibrillation is a common, global problem, with great personal, economic and social burdens. As populations age it increases in prevalence and becomes another condition that requires careful chronic management to ensure its effects are minimised. Assessment of the risk of stroke using well established risk prediction models is being aided by modern computerised databases and the choice of drugs to prevent strokes is ever expanding to try and improve the major cause of morbidity in AF. In addition, newer drugs for controlling rhythm are available and guidelines are constantly changing to reflect this. As well as medications, modern techniques of electrophysiology are becoming more widely embraced worldwide to provide more targeted treatment for the underlying pathophysiology. In this review we consider these factors to concisely describe how AF can be successfully managed.

Loading

Article metrics loading...

/content/journals/10.5339/gcsp.2013.24
2013-08-01
2019-09-16
Loading full text...

Full text loading...

/deliver/fulltext/gcsp/2013/2/gcsp.2013.24.html?itemId=/content/journals/10.5339/gcsp.2013.24&mimeType=html&fmt=ahah

References

  1. [1]. Ruigomez   A., , Johansson   S., , Wallander   M-A., , Rodriguez   LAG. . Incidence of chronic atrial fibrillation in general practive and its treatment pattern. . J Clin Epidemiol . 2002; ;55: 4 : 358– 363
    [Google Scholar]
  2. [2]. NICE clinical guideline 36 Costing Report. 2006
  3. [3]. Kannel   WB., , Wolf   PA., , Benjamin   EJ., , Levy   D. . Prevalence, incidence, prognosis and predisposing conditions for atrial fibrillation: population based estimates. . Am J Cardiol . 1998; ;82: 8A : 2N– 9N
    [Google Scholar]
  4. [4]. Heeringa   J., , van der Kuip   DA., , Hofman   A., , Kors   JA., , van Herpen   G., , Stricker   BH., , Stijnen   T., , Lip   GY., , Witteman   JC. . Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. . Euro Heart J . 2006; ;27: 8 : 949– 953
    [Google Scholar]
  5. [5]. Majeed   A., , Moser   K., , Carroll   K. . Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994–1998: analysis of data from the general practice research database. . Heart . 2001; ;86: 3 : 284– 288
    [Google Scholar]
  6. [6]. Stewart   S., , Hart   CL., , Hole   DJ., , McMurray   JJV. . Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. . Heart . 2001; ;86: : 516– 521
    [Google Scholar]
  7. [7]. Fuster   V., , Ryda´n   LE., , Cannom   DS., , Crijns   HJ., , Curtis   AB., , Ellenbogen   KA., , Halperin   JL., , Leeuzey   JY., , Kay   GN., , Lowe   JE., , Olsson   SB., , Prystowsky   EN., , Tamargo   JL., , Wann   S., , Task Force on Practice Guidelines, American College of Cardiology/American Heart Association; Committee for Practice Guidelines, European Society of Cardiology; European Heart Rhythm Association; Heart Rhythm Society. . ACC/AHA/ESC guidelines. . Eur Heart J . 2006; ;27: : 1979– 2030
    [Google Scholar]
  8. [8]. Go   AS., , Hylek   EM., , Phillips   KA., , Chang   Y., , Henault   LE., , Selby   JV., , Singer   DE. . Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. . JAMA . 2001; ;285: : 2370– 2375
    [Google Scholar]
  9. [9]. Miyasaka   Y., , Barnes   ME., , Gersh   BJ., , Cha   SS., , Bailey   KR., , Abhayaratna   WP., , Seward   JB., , Tsang   TS. . Secular trends in incidence of atrial fibrillation in OlmstedCounty, Minnesota, 1980–2000, and implications on the projections for future prevalence. . Circulation . 2006; ;114: 2 : 119– 125
    [Google Scholar]
  10. [10]. Wolf   PA., , Abbott   RD., , Kannel   WB. . Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. . Stroke . 1991; ;22: 8 : 983– 988
    [Google Scholar]
  11. [11]. NHS Improvement. June 2009. Available at http://www.improvement.nhs.uk/heart/Portals/0/documents2009/AF_Commissioning_Guide_v2.pdf. Accessed August 24, 2012
  12. [12]. Marini   A., , De Santis   F., , Sacco   S., , Russo   T., , Olivieri   L., , Totaro   R., , Carolei   A. . Contribution of atrial fibrillation to incidence and outcomes of ischaemic stroke: results from a population-based study. . Stroke . 2005; ;36: 6 : 1115– 1119
    [Google Scholar]
  13. [13]. Jorgensen   HS., , Nakayama   H., , Reith   J., , Raaschou   HO., , Olsen   TS. . Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. . Stroke . 1996; ;27: 10 : 1765– 1769
    [Google Scholar]
  14. [14]. Dulli   DA., , Stanko   H., , Levine   RL. . Atrial fibrillation is associated with severe acute ischaemic stroke. . Neuroepidemiology . 2003; ;22: : 118– 123
    [Google Scholar]
  15. [15]. Wang   PH., , Levy   D., , D'Agostino   RB Sr., , Wolf   PA., , Vasan   RS., , Benjamin   EJ. . Obesity and the risk of new-onset atrial fibrillation. . JAMA . 2004; ;292: 20 : 2471– 2477
    [Google Scholar]
  16. [16]. WHO Fact Sheet No 311. May 2012. Available at http://www.who.int/mediacentre/factsheets/fs311/en/. Accessed August 24, 2012
  17. [17]. Gage   BF., , Waterman   AD., , Shannon   W., , Boechler   M., , Rich   MW., , Radford   MJ. . Validation of clinical classification schemes for predicting stroke. . JAMA . 2001; ;285: 22 : 2864– 2870
    [Google Scholar]
  18. [18]. Gage   BF., , van Walraven   C., , Pearce   L., , Hart   RG., , Koudstaal   PJ., , Boode   BSP., , Peterson   P. . Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. . Circulation . 2004; ;110: 16 : 2287– 2292
    [Google Scholar]
  19. [19]. Lip   GY., , Nieuwlaat   R., , Pisters   R., , Lane   DA., , Crijns   HJ. . Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor based approach: the euro heart survey on atrial fibrillation. . Chest . 2010; ;137: 2 : 263– 272
    [Google Scholar]
  20. [20]. Lip   GY., , Frison   L., , Halperin   JL., , Lane   DA. . Identifying patients at high risk for stroke despite anticoagulation. . Stroke . 2010; ;41: : 2731– 2738
    [Google Scholar]
  21. [21]. Olesen   JB., , Lip   GY., , Hansen   ML., , Hansen   PR., , Tolstrup   JS., , Lindhardsen   J., , Selmer   C., , Ahlehoff   O., , Olsen   AM., , Gislason   GH., , Torp-Pedersen   C. . Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. . BMJ . 2011; ;342: : d142
    [Google Scholar]
  22. [22]. Botto   GL., , Padeletti   L., , Santini   M., , Capucci   A., , Gulizia   M., , Zolezzi   F., , Favale   S., , Molon   G., , Ricci   R., , Biffi   M., , Russo   G., , Vimercati   M., , Corbucci   G., , Boriani   G. . Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. . J Cardiovasc Electrophysiol . 2009; ;20: 3 : 241– 248
    [Google Scholar]
  23. [23]. Go   AS., , Fang   MC., , Udaltsova   N., , Chang   Y., , Pomernacki   NK., , Borowsky   L., , Singer   DE., , ATRIA Study Investigators. . Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. . Circulation . 2009; ;119: 10 : 1363– 1369
    [Google Scholar]
  24. [24]. Atrial Fibrillation Investigators . Echocardiographic predictors of stroke in patients with atrial fibrillation. . Arch Intern Med . 1998; ;158: 12 : 1316– 1320
    [Google Scholar]
  25. [25]. SPAF Investigators . Transesophageal echocardiographic correlates of thromboembolism in high risk patients with nonvalvular atrial fibrillation. . Ann Intern Med . 1998; ;128: : 639– 647
    [Google Scholar]
  26. [26]. Camm   AJ., , Lip   GY., , De Caterina   R., , Savelieva   I., , Atar   D., , Hohnloser   SH., , Hindricks   G., , Kirchhof   P., , ESC Committee for Practice Guidelines (CPG)., , Bax   JJ., , Baumgartner   H., , Ceconi   C., , Dean   V., , Deaton   C., , Fagard   R., , Funck-Brentano   C., , Hasdai   D., , Hoes   A., , Kirchhof   P., , Knuuti   J., , Kolh   P., , McDonagh   T., , Moulin   C., , Popescu   BA., , Reiner   Z., , Sechtem   U., , Sirnes   PA., , Tendera   M., , Torbicki   A., , Vahanian   A., , Windecker   S., , Document Reviewers., , Vardas   P., , Al-Attar   N., , Alfieri   O., , Angelini   A., , Blömstrom-Lundqvist   C., , Colonna   P., , De Sutter   J., , Ernst   S., , Goette   A., , Gorenek   B., , Hatala   R., , Heidbüchel   H., , Heldal   M., , Kristensen   SD., , Kolh   P., , Le Heuzey   JY., , Mavrakis   H., , Mont   L., , Filardi   PP., , Ponikowski   P., , Prendergast   B., , Rutten   FH., , Schotten   U., , Van Gelder   IC., , Verheugt   FW. . 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. . Eur Heart J . 2012; ;33: 21 : 2719– 2747 , doi: 10.1093/eurheartj/ehs253. Epub August 24, 2012
    [Google Scholar]
  27. [27]. You   JJ., , Singer   DE., , Howard   PA., , Lane   DA., , Eckman   MH., , Fang   MC., , Hylek   EM., , Schulman   S., , Go   AS., , Hughes   M., , Spencer   FA., , Manning   WJ., , Halperin   JL., , Lip   GY., , American College of Chest Physicians. . Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. . Chest . 2012; ;141: : e531S– e575S
    [Google Scholar]
  28. [28]. Pisters   R., , Lane   DA., , Nieuwlaat   R., , de Vos   CB., , Crijns   HJ., , Lip   GY. . A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro heart survey. . Chest . 2010; ;138: 5 : 1093– 1100
    [Google Scholar]
  29. [29]. Olesen   JB., , Lip   GY., , Hansen   PR., , Lindhardsen   J., , Ahlehoff   O., , Andersson   C., , Weeke   P., , Hansen   ML., , Gislason   GH., , Torp-Pedersen   C. . Bleeding risk in “real world” patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort. . J Thromb Haemost . 2011; ;9: 8 : 1460– 1467
    [Google Scholar]
  30. [30]. Fang   MC., , Go   AS., , Chang   Y., , Borowsky   LH., , Pomernacki   NK., , Udaltsova   N., , Singer   DE. . A new risk scheme to predict warfarin-associated hemorrhage, The ATRIA (anticoagulation and risk factors in atrial fibrillation) study. . J Am Coll Cardiol . 2011; ;58: 4 : 395– 401
    [Google Scholar]
  31. [31]. Mant   J., , Hobbs   FD., , Fletcher   K., , Roalfe   A., , Fitzmaurice   D., , Lip   GY., , Murray   E., , BAFTA investigators; Midland Research Practices Network (MidReC). . Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham atrial fibrillation treatment of the aged study, BAFTA): a randomised control trial. . Lancet . 2007; ;370: 9586 : 493– 503
    [Google Scholar]
  32. [32]. Connolly   SJ., , Ezekowitz   MD., , Yusuf   S., , Eikelboom   J., , Oldgren   J., , Parekh   A., , Pogue   J., , Reilly   PA., , Themeles   E., , Varrone   J., , Wang   S., , Alings   M., , Xavier   D., , Zhu   J., , Diaz   R., , Lewis   BS., , Darius   H., , Diener   HC., , Joyner   CD., , Wallentin   L., , RE-LY Steering Committee and Investigators. . Dabigatran versus warfarin in patients with atrial fibrillation. . N Engl J Med . 2009; ;361: 12 : 1139– 1151
    [Google Scholar]
  33. [33]. Wallentin   L., , Yusuf   S., , Ezekowitz   MD., , Alings   M., , Flather   M., , Franzosi   MG., , Pais   P., , Dans   A., , Eikelboom   J., , Oldgren   J., , Pogue   J., , Reilly   PA., , Yang   S., , Connolly   SJ., , RE-LY investigators. . Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. . Lancet . 2010; ;376: 9745 : 975– 983
    [Google Scholar]
  34. [34]. NICE technology appraisal guidance 249. March 2012. Available at www.guidance.nice.org.uk/ta249. Accessed August 18, 2013
  35. [35]. Patel   MR., , Mahaffey   KW., , Garg   J., , Pan   G., , Singer   DE., , Hacke   W., , Breithardt   G., , Halperin   JL., , Hankey   GJ., , Piccini   JP., , Becker   RC., , Nessel   CC., , Paolini   JF., , Berkowitz   SD., , Fox   KA., , Califf   RM., , ROCKET AF Investigators. . Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. . N Engl J Med . 2011; ;365: 10 : 883– 891
    [Google Scholar]
  36. [36]. NICE technology appraisal guidance 256. May 2012. Available at www.guidance.nice.org.uk/ta256. Accessed August 18, 2013
  37. [37]. Connolly   SJ., , Eikelboom   J., , Joyner   C., , Diener   HC., , Hart   R., , Golitsyn   S., , Flaker   G., , Avezum   A., , Hohnloser   SH., , Diaz   R., , Talajic   M., , Zhu   J., , Pais   P., , Budaj   A., , Parkhomenko   A., , Jansky   P., , Commerford   P., , Tan   RS., , Sim   KH., , Lewis   BS., , Van Mieghem   W., , Lip   GY., , Kim   JH., , Lanas-Zanetti   F., , Gonzalez-Hermosillo   A., , Dans   AL., , Munawar   M., , O'Donnell   M., , Lawrence   J., , Lewis   G., , Afzal   R., , Yusuf   S., , AVERROES Steering Committee and Investigators. . Apixaban in patients with atrial fibrillation. . N Engl J Med . 2011; ;364: 9 : 806– 817
    [Google Scholar]
  38. [38]. Granger   CB., , Alexander   JH., , McMurray   JJ., , Lopes   RD., , Hylek   EM., , Hanna   M., , Al-Khalidi   HR., , Ansell   J., , Atar   D., , Avezum   A., , Bahit   MC., , Diaz   R., , Easton   JD., , Ezekowitz   JA., , Flaker   G., , Garcia   D., , Geraldes   M., , Gersh   BJ., , Golitsyn   S., , Goto   S., , Hermosillo   AG., , Hohnloser   SH., , Horowitz   J., , Mohan   P., , Jansky   P., , Lewis   BS., , Lopez-Sendon   JL., , Pais   P., , Parkhomenko   A., , Verheugt   FW., , Zhu   J., , Wallentin   L., , ARISTOTLE Committees and Investigators. . Apixaban versus warfarin in patients with atrial fibrillation. . N Engl J Med . 2011; ;365: 11 : 981– 992
    [Google Scholar]
  39. [39]. Eerenberg   ES., , Kamphuisen   PW., , Sijpkens   MK., , Meijers   JC., , Buller   HR., , Levi   M. . Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate. . Circulation . 2011; ;124: : 1573– 1579
    [Google Scholar]
  40. [40]. van Ryn   J., , Litzenburger   T., , Gan   G., , Coble   K., , Schurer   J. . In vitro Characterization, Pharmacokinetics and Reversal of supratherapeutic doses of dabigatran-induced bleeding in rats by a specific antibody fragment antidote to dabigatran. . Oral Presentation 9928. Presented on 5 November 2012 at the American Heart Association Scientific Sessions 2012
  41. [41]. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery , Camm   AJ., , Kirchhof   P., , Lip   GY., , Schotten   U., , Savelieva   I., , Ernst   S., , Van Gelder   IC., , Al-Attar   N., , Hindricks   G., , Prendergast   B., , Heidbuchel   H., , Alfieri   O., , Angelini   A., , Atar   D., , Colonna   P., , De Caterina   R., , De Sutter   J., , Goette   A., , Gorenek   B., , Heldal   M., , Hohloser   SH., , Kolh   P., , Le Heuzey   JY., , Ponikowski   P., , Rutten   FH. . Guidelines for the management of atrial fibrillation. . Euro Heart J . 2010; ;31: : 2369– 2429
    [Google Scholar]
  42. [42]. The AFFIRM investigators . A comparison of rate control and rhythm control in patients with atrial fibrillation. . N Engl J Med . 2002; ;347: : 1825– 1833
    [Google Scholar]
  43. [43]. Corley   SD., , Epstein   AE., , DiMarco   JP., , Domanski   MJ., , Geller   N., , Greene   HL., , Josephson   RA., , Kellen   JC., , Klein   RC., , Krahn   AD., , Mickel   M., , Mitchell   LB., , Nelson   JD., , Rosenberg   Y., , Schron   E., , Shemanski   L., , Waldo   AL., , Wyse   DG., , AFFIRM Investigators. . Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. . Circulation . 2004; ;109: 2 : 1509– 1513
    [Google Scholar]
  44. [44]. Lafuente-Lafuente   C., , Mouly   S., , Longas-Tejero   MA., , Bergmann   JF. . Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. . Cochrane Database Syst Rev . 2012; ;5: : CD005049
    [Google Scholar]
  45. [45]. Hohnloser   SH., , Crijns   HJ., , van Eickels   M., , Gaudin   C., , Page   RL., , Torp-Pedersen   C., , Connolly   SJ., , ATHENA Investigators. . Effect of dronedarone on cardiovascular events in atrial fibrillation. . N Engl J Med . 2009; ;360: 7 : 668– 678
    [Google Scholar]
  46. [46]. Connolly   SJ., , Camm   AJ., , Halperin   JL., , Joyner   C., , Alings   M., , Amerena   J., , Atar   D., , Avezum   Á., , Blomström   P., , Borggrefe   M., , Budaj   A., , Chen   SA., , Ching   CK., , Commerford   P., , Dans   A., , Davy   JM., , Delacrétaz   E., , Di Pasquale   G., , Diaz   R., , Dorian   P., , Flaker   G., , Golitsyn   S., , Gonzalez-Hermosillo   A., , Granger   CB., , Heidbüchel   H., , Kautzner   J., , Kim   JS., , Lanas   F., , Lewis   BS., , Merino   JL., , Morillo   C., , Murin   J., , Narasimhan   C., , Paolasso   E., , Parkhomenko   A., , Peters   NS., , Sim   KH., , Stiles   MK., , Tanomsup   S., , Toivonen   L., , Tomcsányi   J., , Torp-Pedersen   C., , Tse   HF., , Vardas   P., , Vinereanu   D., , Xavier   D., , Zhu   J., , Zhu   JR., , Baret-Cormel   L., , Weinling   E., , Staiger   C., , Yusuf   S., , Chrolavicius   S., , Afzal   R., , Hohnloser   SH., , PALLAS Investigators. . Dronedarone in permanent high risk atrial fibrillation. . N Engl J Med . 2011; ;365: 24 : 2268– 2276
    [Google Scholar]
  47. [47]. Pappone   C., , Rosanio   S., , Augello   G., , Gallus   G., , Vicedomini   G., , Mazzone   P., , Gulletta   S., , Gugliotta   F., , Pappone   A., , Santinelli   V., , Tortoriello   V., , Sala   S., , Zangrillo   A., , Crescenzi   G., , Benussi   S., , Alfieri   O. . Mortality, morbidity and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. . J Am Coll Cardiol . 2003; ;42: 2 : 185– 197
    [Google Scholar]
  48. [48]. Calkins   H., , Reynolds   MR., , Spector   P., , Sondhi   M., , Xu   Y., , Martin   A., , Williams   CJ., , Sledge   I. . Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. . Circ Arrhythm Electrophysiol . 2009; ;2: 4 : 349– 361
    [Google Scholar]
  49. [49]. Stabile   G., , Bertaglia   E., , Senatore   G., , De Simone   A., , Zoppo   F., , Donnici   G., , Turco   P., , Pascotto   P., , Fazzari   M., , Vitale   DF. . Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation for the cure of atrial fibrillation study). . Euro Heart J . 2006; ;27: 2 : 216– 221
    [Google Scholar]
  50. [50]. Pappone   C., , Augello   G., , Sala   S., , Gugliotta   F., , Vicedomini   G., , Gulletta   S., , Paglino   G., , Mazzone   P., , Sora   N., , Greiss   I., , Santagostino   A., , LiVolsi   L., , Pappone   N., , Radinovic   A., , Manguso   F., , Santinelli   V. . A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF study. . J Am Coll Cardiol . 2006; ;48: 11 : 2340– 2347
    [Google Scholar]
  51. [51]. Cosedis Nielsen   J., , Johannessen   A., , Raatikainen   P., , Hindricks   G., , Walfridsson   H., , Kongstad   O., , Pehrson   S., , Englund   A., , Hartikainen   J., , Mortensen   LS., , Hansen   PS. . Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. . N Engl J Med . 2012; ;367: : 1587– 1595
    [Google Scholar]
  52. [52]. Wazni   OM., , Marrouche   NF., , Martin   DO., , Verma   A., , Bhargava   M., , Saliba   W., , Bash   D., , Schweikert   R., , Brachmann   J., , Gunther   J., , Gutleben   K., , Pisano   E., , Potenza   D., , Fanelli   R., , Raviele   A., , Themistoclakis   S., , Rossillo   A., , Bonso   A., , Natale   A. . Radiofrequency ablation vs. antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. . JAMA . 2005; ;293: 21 : 2634– 2640
    [Google Scholar]
  53. [53]. Weerasooriya   R., , Khairy   P., , Litalien   J., , Macle   L., , Hocini   M., , Sacher   F., , Lellouche   N., , Knecht   S., , Wright   M., , Nault   I., , Miyazaki   S., , Scavee   C., , Clementy   J., , Haissaguerre   M., , Jais   P. . Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow up?.   J Am Coll Cardiol . 2011; ;57: 2 : 160– 166
    [Google Scholar]
  54. [54]. Pappone   C., , Vicedomini   G., , Augello   G., , Manguso   F., , Saviano   M., , Baldi   M., , Petretta   A., , Giannelli   L., , Calovic   Z., , Guluta   V., , Tavazzi   L., , Santinelli   V. . Radiofrequency catheter ablation and antiarrhythmic drug therapy: a prospective, randomised, 4 year follow up trial: the APAF study. . Circ Arrhythm Electrophysiol . 2011; ;4: 6 : 808– 814
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/gcsp.2013.24
Loading
/content/journals/10.5339/gcsp.2013.24
Loading

Data & Media loading...

Supplementary File 1

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error